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Abstract. Records of 3,449 patients admitted to Karitas Hospital at Waitabula in eastern Indonesia with microscopy-
confirmed malaria through 2008 and 2009 were systematically reviewed. Falciparum, vivax, and mixed species malaria
occurred among 1,541, 1,837, and 71 admissions, respectively. Among these, 400 (26%), 199 (11%), and 15 (21%) had
serious illness. Fatalities occurred in 46 (12%), 18 (9%), and 2 (13%) of these patients, respectively. Although patients
with a diagnosis of falciparum malaria were more likely to have serious illness compared with those with vivax malaria
(odds ratio [OR] = 2.9; 95% confidence interval [CI]: 2.4–3.5), this diagnosis nonetheless was associated with 32% of
serious illness and 27% of fatalities. Among the seriously ill with a diagnosis of falciparum or vivax malaria, no significant
difference in risk of death occurred (OR = 1.3; 95% CI: 0.7–2.5). Serious and fatal illness was predominantly anemia or
altered mental state syndromes among patients with either of the species diagnoses. Plasmodium vivax was associated with
a substantial share of the burden of morbidity and mortality caused by malaria in this hypo- to meso-endemic community.
INTRODUCTION
Plasmodium vivax malaria has long been considered only
rarely fatal.1 Recent studies, however, have revitalized the
argument that P. vivax may often become pernicious and
directly threaten life.2 As the causal agent in 100–400 million
clinical attacks each year,3 and threatening almost three bil-
lion people exposed to endemic risk,4 this parasite obviously
bears consideration as a major global health concern.
Recent work from India emphasizes the uncertainty in esti-
mates of mortality caused by malaria. One study used verbal
autopsy methods and the findings suggested underestimation
of the burden of malaria mortality in that nation by at least
9- and as much as 19-fold5; given the broad presumption of
the benign character of P. vivax, perhaps few would credit
even a minor share of mortality attributed to malaria to this
parasite. Nonetheless, recent retrospective and prospective
hospital-based studies6–14 involving 18,141 patients, 13% and
14% were classified as having serious illness with a diagnosis
of Plasmodium falciparum or P. vivax, with 10% and 7% of
those ending in death, respectively. Such evaluations, com-
paring relative burdens associated with the two species, may
mitigate some of the many confounding factors (misdiagnosis,
concurrent infections, and underlying disease) inherent to
endemic zones like Indonesia.
In 2006 Indonesia reported 347,597 confirmed and sus-
pected malaria cases to the World Health Organization
(WHO), most of those having a laboratory-confirmed diag-
nosis.15 The World Health Organization estimated 2.5 mil-
lion clinical attacks in Indonesia for that year. According to
Malaria Atlas Project (MAP), the annual number of clinical
attacks of P. falciparum alone was over 12 million, and the
number of Indonesians at risk of P. falciparum in 2007 was
151 million,16 whereas those at risk of P. vivax in 2009 num-
bered 175 million.3 The number of clinical attacks of vivax
malaria among Indonesians has not yet been reliably estimated,
but historically accounts for 46% of prevalent malaria in blood
screening surveys.15 Thus, malaria represents a very substantial
threat to public health in Indonesia, and vivax malaria consti-
tutes a considerable contribution to that broader problem.
Most endemic malaria in Indonesia is relatively low trans-
mission intensity16; to better grasp the relative contributions
of falciparum and vivax malaria to associated morbidity and
mortality in this setting, a retrospective analysis of admissions
to a single hospital in West Sumba, eastern Indonesia, over
2008 and 2009 was conducted.
MATERIALS ANDMETHODS
Study site. Karitas Hospital is located at Waitabula near
the northern coast airport of Tambolaka in West Sumba,
Indonesia. Karitas serves as the primary hospital in that com-
munity, and referral site for health centers throughout much
of West Sumba. The catchment population was ~280,000 peo-
ple. Karitas had 115 beds for inpatient care, surgical capaci-
ties, and a clinical laboratory service. People coming to the
hospital seeking treatment of febrile illness first had blood
smears examined for malaria by microscopy. Technicians
trained and certified as competent both by the Eijkman Insti-
tute for Molecular Biology and U.S. Naval Medical Research
Unit 217 in Jakarta read the blood smears. Once diagnosed
with malaria, patients were referred to a physician for evalu-
ation. They were managed either as an outpatient or admit-
ted for treatment and observation as a malaria inpatient. The
hospital maintained records of diagnosis and treatment of all
of these outpatients and inpatients.
A systematic sampling of villages in West Sumba in 2007
for cross-sectional blood surveys of 8,870 residents of 45 vil-
lages showed wet and dry season prevalence for P. falciparum
of 4.88% and 2.88%, respectively, and 2.16% and 2.14% for
P. vivax.18 Prevalence of malaria among villages ranged from
0% to 34%, however with only four of the 45 villages sam-
pled having prevalence exceed 20% at either wet or dry sea-
son samples.18 Endemic malaria in West Sumba thus typically
occurs at a prevalence of < 5% with relatively little difference
between P. falciparum and P. vivax.
Patient records management. The ethical review boards
of the Eijkman Institute for Molecular Biology and of the
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London School of Hygiene and Tropical Medicine reviewed
the protocol describing this study and approved its conduct.
This retrospective, cross-sectional study retrieved the records
of patients who sought treatment at Karitas Hospital and who
had a laboratory-confirmed malaria diagnosis.
Outpatient and inpatient records for all of 2008 and 2009
were examined. Figure 1 illustrates the numbers of patients
with a microscopically confirmed diagnosis of malaria across
demographic groups for both inpatients and outpatients.
Among 30,142 hospital visits, 2,711 (9%) were confirmed
positive for malaria and managed as outpatients. Another
3,484 (11%) were admitted as inpatients; 35 of those records
were excluded from analysis because of incomplete or illegi-
ble content, and thus 3,449 inpatient records constituted the
study population.
Relevant data from the hospital patient file, with exclusion
of personal identifiers, was directly transferred into two dupli-
cate case report forms (CRF) for each patient by two different
nurse technicians. Each CRF was then manually entered into
an electronic database (EpiData) twice. The four electronic
versions per patient were examined for discrepancies that
were resolved by manual cross-check of the CRF copies and,
if necessary, the hospital patient record. Concordant elec-
tronic CRFs were uploaded to a permanent storage device in
Stata version 11 (Stata, College Station, TX) for analysis.
Classification of patients. Infants were < 12 months of age,
children were < 10 years of age, adolescents were between
10 and 15 years of age, adults were > 15 years of age, and
people > 60 years of age were classified as elderly. Women
were classified as pregnant with affirmative evidence in the
record; absent of such evidence they were classified as not
pregnant. The malaria microscopists did not count and record
parasite densities from blood films. Instead they used a scoring
system based on the number of parasites seen among micro-
scopic fields of the thick film under oil immersion magnifica-
tion (1,000 +) as follows: 1+ = 1–10 parasites/100 fields, 2+ =
11–100 parasites/100 fields, 3+ = 1–10 parasites/field, and 4+ ³
10 parasites/field. The 4+ score may be estimated at > 6,000/mL
by assuming that each high power field represents ~1/600th of
a microliter.19 Although scores were available for almost all
patient records, 6,000 parasites/mL was too low a threshold for
classifying patients as being seriously ill on the basis of relatively
heavy parasitemia. The parameter was applied to examine the
frequencies of relatively high parasitemia between the two spe-
cies among patients classified as not serious, serious, or fatal.
Classification of disease severity did not comply with stan-
dard definitions such as those provided by WHO because
most measurements required for that definition were not
available at Karitas Hospital. Strict application of it would
have caused exclusion of most records as incomplete. There-
fore, before examining the records, a system for classification
of illness associated with a diagnosis of malaria was developed
using what was understood to be broadly available informa-
tion at Karitas.
Patients meeting the following criteria were classified as
having NOT SERIOUS illness:
1. Not admitted to intensive care unit; and
2. No record of seizure or altered consciousness; and
3. No record of severe anemia (< 5 or < 7 g/dL for children
or adults) or transfusion; and
4. No record indicating pulmonary distress; and
5. No record indicating renal failure; and
6. No record indicating hepatic failure.
Patients were classified as having SERIOUS illness in accor-
dance with the following:
1. Treated in any ward; and
2. Intravenous (IV) antimalarial therapy; or
3. Record of seizure or altered consciousness; or
4. Record of severe anemia (< 5 and < 7 g/dL for children or
adults) or transfusion; or
5. Record indicating pulmonary distress; or
6. Record indicating renal failure; or
7. Record indicating hepatic failure.
Patients classified as having SERIOUS malaria were fur-
ther classified according to the apparent organ of primary ill-
ness. All of these classifications were made on the basis of
notes or data in the patient record. The following guided these
syndromic classifications:
1. Severe anemia: Patient record contained notes document-
ing blood transfusion or a laboratory measurement of
hemoglobin < 5 g/dL for children and < 7 g/dL for adults.
2. Altered mental state: Patient record contained notes doc-
umenting patient was disoriented, stuporous, delirious,
unconscious, comatose, suffering at least two seizures, and
receiving intravenous or intramuscular antimalarial therapy.
3. Respiratory distress: Patient record contained notes describ-
ing labored or rapid breathing (> 50 breaths/minute).
4. Hepatic illness: Patient record contained notes describing
physical signs of jaundice or containing record of labora-
tory values aspartate aminotransferase (SGOT) and alanine
aminotransferase (SGPT) elevated 2.5-fold above normal
values (0–40; 0–50).
5. Bleeding: Patient record contained notes describing patient
had spontaneous bleeding from any site.
6. Prostration: Patient record contained notes describing
patient was unable to sit up or stand without assistance.
7. Double syndrome: Any two of the above.
8. Multiple syndromes: More than two of the above.
Patients were classified as FATAL only with evidence that
death occurred in the hospital and the attending physician
recorded malaria as the cause of death.
Figure 1. Graphs illustrate the number of outpatients (left) and
inpatients (right) among demographic groups at Karitas Hospital,
West Sumba, Indonesia during 2008 and 2009.
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Statistical analysis. The statistical analysis used Stata ver-
sion 11. Descriptive analyses were performed to determine
the proportions for categorical data. Odds ratios (OR), 95%
confidence interval (CI), and P values comparing rates and
proportions were calculated using c2 contingency tables and
Fisher’s exact test. The CI that included 1 and/or the P values
that were > 0.05 were considered insignificant.
RESULTS
Figure 2 illustrates monthly admissions to the hospital for
malaria over the 24 months of analysis by species of diagnosis.
Table 1 lists the distribution of admissions, serious illness, and
death with a diagnosis of P. falciparum, P. vivax, or mixed
infections of these two species among demographic groups.
Figure 2. Graph illustrates monthly numbers of admissions to Karitas Hospital in West Sumba, eastern Indonesia, ascertained by a retrospec-
tive review of admission records. The lines show all admissions (X, purple), falciparum malaria (diamond, blue), vivax malaria (square, red), and
mixed infections of these two species (triangle, green).
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Among the 3,449 patients admitted with a diagnosis of malaria,
614 (18%) were classified as having serious disease, and
66 (11%) of those patients died. Falciparum malaria occurred
among 45% of admissions, 65% of serious disease, and 70%
of deaths, whereas vivax malaria occurred in 53%, 32%, and
27% of these, respectively. No significant differences appeared
between rates of serious illness with a diagnosis of P. falciparum
versus mixed species infection (26% versus 23%; P = 0.527),
and the same was true of case fatality rates (12% versus
13%; P = 0.905). Mixed infections were excluded from fur-
ther analyses comparing trends in morbidity and mortality
between species.
Presumptive antibiotic therapy was not routinely adminis-
tered with a diagnosis of malaria. Among the 220 patient
files randomly selected for the survey of antibiotic therapy
(110 P. falciparum and 110 P. vivax), 85% and 72% received
no antibiotics, respectively. Antibiotic therapy was with amoxi-
cillin, ampicillin, or ciprofloxacin.
Table 2 lists ORs for risk of serious illness with a diagno-
sis of P. falciparum relative to P. vivax among demographic
groups. Overall, patients admitted with a diagnosis of fal-
ciparum malaria were 2.9 times (95% CI: 2.4–3.5) more likely
to be classified as having serious illness compared with admis-
sion with a diagnosis of vivax malaria. This trend was strongest
among infants, children, and adolescents (OR 3.0 to 8.3), and
weakest among adults and the elderly (OR 1.3 and 0.4). Preg-
nant women were no more likely to have serious illness with a
diagnosis of falciparum compared with vivax malaria (OR =
0.7; 95% CI: 0.3–2.1), and this was also true among women
classified as not pregnant (OR = 1.4; 95% CI: 0.8–2.4). Com-
pared with not pregnant women, pregnant women with a diag-
nosis of falciparum malaria or of vivax malaria were similarly
likely to be classified as having serious disease (OR = 0.9; 95%
CI: 0.4–2.1, and OR = 0.5; 95% CI: 0.2–1.2, respectively).
Infants, children, and adolescents contributed 82% of
serious illness with a diagnosis of P. falciparum and 54% of
that for P. vivax. Overall, these young age groups accounted
for 73% of serious illness and 77% of fatalities, and repre-
sented only 55% of the general population. They were 4.5 times
(95% CI: 3.3–6.1) more likely to have serious outcomes with a
Table 1
Morbidity and mortality associated with falciparum and vivax malaria during 2008 and 2009 at Karitas Hospital, West Sumba*
Demographic groups
Admissions Serious disease (% of admissions) Death (% of serious)
PF PV Mix PF PV Mix PF PV Mix
Infants (< 12 months) 64 198 5 30 (47) 19 (10) 1 (20) 3 (10) 3 (16) 0 (0)
Children (³ 12 months and < 10 years) 658 557 31 264 (40) 75 (14) 7 (23) 33 (13) 6 (8) 1 (14)
Adolescents (³ 10 and < 15 years) 150 149 9 33 (22) 13 (9) 4 (44) 5 (15) 0 (0) 0 (0)
Adults (³ 15 and < 60 years) 633 808 23 70 (11) 70 (9) 2 (9) 5 (7) 7 (10) 0 (0)
Men 310 368 11 28 (9) 24 (7) 2 (18) 3 (11) 2 (8) 0 (0)
Women 323 440 12 42 (13) 46 (10) 0 (0) 2 (5) 5 (11) 0 (0)
Not pregnant 234 389 11 30 (13) 37 (10) 0 (0) 1 (3) 4 (11) 0 (0)
Pregnant 89 51 1 12 (14) 9 (18) 0 (0) 1 (8) 1 (11) 0 (0)
Elderly (³ 60 years) 36 125 3 3 (8) 22 (18) 1 (33) 0 (0) 2 (9) 1 (100)
Total 1,541 1,837 71 400 (26) 199 (11) 15 (21) 46 (12) 18 (9) 2 (13)
*PF = Plasmodium falciparum; PV = Plasmodium vivax.
TABLE 2
Odds of serious illness associated with falciparum versus vivax malaria among groups*
All age groups
Serious
Infants (< 12 months)
Serious
Yes No Yes No
Plasmodium falciparum 400 1,141 P. falciparum 30 34
Plasmodium vivax 199 1,638 P. vivax 19 179
OR (95% CI) 2.9 (2.4–3.5) OR (95% CI) 8.3 (4.0–17.4)
Children (³ 12 months and < 10 years)
Serious
Adolescents (³ 10 and < 15 years)
Serious
Yes No Yes No
P. falciparum 264 394 P. falciparum 33 117
P. vivax 75 482 P. vivax 13 136
OR (95% CI) 4.3 (3.2–5.8) OR (95% CI) 3.0 (1.4–6.4)
Adults (³ 15 and < 60 years)
Serious
Elderly (³ 60 years)
Serious
Yes No Yes No
P. falciparum 70 563 P. falciparum 3 33
P. vivax 70 738 P. vivax 22 103





Yes No Yes No
P. falciparum 12 77 P. falciparum 30 204
P. vivax 9 42 P. vivax 37 352
OR (95% CI) 0.7 (0.3–2.1) OR (95% CI) 1.4 (0.8–2.4)
*OR = odds ratio; CI = confidence interval.
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diagnosis of P. falciparum compared with adults and the elderly
with the same diagnosis. The same was not true for a diagnosis
of P. vivax, where risk of serious illness appeared more evenly
distributed between infants/children/adolescents versus adults/
elderly (OR = 1.2; 95% CI: 0.8–1.7). Figure 3 illustrates the
distinct age-related susceptibility to serious illness with a diag-
nosis of falciparum malaria among admitted patients, and the
absence of such an effect with a diagnosis of vivax malaria.
Table 3 lists ORs for fatal outcomes with serious falciparum-
versus vivax-associated illness. The odds of death among seri-
ously ill patients were no different between diagnoses of the
two species (OR = 1.3; 95% CI: 0.7–2.5).
Figure 4 illustrates the distribution of syndromes among all
patients having falciparum or vivaxmalaria. Among 400 patients
with a diagnosis of falciparum malaria and classified as having
serious illness, severe anemia (266) and altered mental state
(137) overwhelmingly dominated among other possible syn-
drome classifications. The pattern was similar among patients
with vivax malaria; severe anemia (77) and altered mental state
(86) were dominant among the 199 patients. The majority of
patients with severe anemia received transfusions; 92% and
84% for falciparum and vivax malaria patients, respectively.
Other syndromes associated with falciparum and vivax malaria
were respiratory distress – 11 and 10; hepatic illness – 4 and 2;
bleeding – 2 and 6; and prostration – 1 and 7, respectively.
Syndromes among the few serious mixed infections (15) were
essentially similar to those for falciparum and vivax malaria.
Significant differences in the relative frequencies of syndromes
between children and adults appeared only with altered mental
state in vivax malaria (55% and 29%, respectively, P = 0.02).
Most patients with serious illness and a diagnosis of falciparum
(90%) or vivax (96%) malaria presented with only a single
syndrome, and only one patient presented with more than two
syndromes (Table 4). Most of the fatal cases with a diagnosis
of vivax malaria showed only a single syndrome (16 of 18),
and this was also true of fatalities associated with falciparum
malaria (36 of 46).
Figure 5 illustrates available hemoglobin measurements
among seriously ill and fatal cases (any syndrome). The distri-
bution of these measurements around the respective thresholds
for severe anemia was similar across species of diagnosis, demo-
graphic group, and clinical severity of disease. One possible
exception was the absence of severe anemia among fatal cases
with a diagnosis of P. vivax in children, but the few cases did
not permit adequate statistical inference on this distribution.
Figure 6 illustrates the distribution of parasite counts scored
4+ and therefore higher than ~6,000 parasites/mL blood among
not serious, serious, and fatal disease associated with fal-
ciparum or vivax malaria. Many patients with serious and fatal
falciparum malaria had relatively high parasitemias (33–59%)
and the proportion having > 6,000/mL increased with increas-
ingly serious illness. In contrast, a minority of patients with
vivax malaria had high parasitemia scores (< 6%), and these
relatively very low frequencies increased with increasingly
serious illness (0.6–6%).
DISCUSSION
This study analyzed trends in morbidity and mortality
among patients admitted to a tertiary care referral hospital at
West Sumba in eastern Indonesia with a microscopic diag-
nosis of malaria during 2008 and 2009. The relatively com-
pact and well-resourced Karitas Hospital provided access to
remarkably thorough and complete patient files, coupled with
systematic and certifiably competent microscopic diagnoses
of malaria. Like most retrospective hospital-based analyses
of illness associated with malaria, this one applied an impro-
vised and simplified definition of serious illness with malaria.
Although this requirement imposes uncertainty with respect
to comparability of the risk findings with those in other hos-
pitals, the uniform application of this definition to patients at
Karitas Hospital nonetheless provides useful comparisons of
risk of serious illness associated with infection by the species
of plasmodia. Examining the relative burdens of risk of serious
and fatal illness associated with P. falciparum and P. vivax
malaria was the primary objective of this study.
Possible confounding of these findings by co-infections rep-
resents an important limitation with this study. Apart from
the possibility of cryptic co-infection with P. falciparum, which
may be very difficult to observe by microscopy, other endemic
infectious diseases occurred on Sumba. None of these possi-
bilities was ruled out by laboratory investigation, and some of
these agents may have been the primary cause of illness
among the patients diagnosed with malaria. Exhaustive labo-
ratory investigations of patients with malaria elsewhere have
demonstrated substantial contributions by co-infections or
co-morbidities for both P. falciparum and P. vivax.20,21
Clinical and laboratory evidence in this study and others
suggests that vivax malaria could have been an important con-
tributing determinant of serious illness among patients with
that diagnosis. The densities of parasitemia among all classes
of illness with vivax malaria were consistently and strikingly
Figure 3. Age-dependent diminishing risk of being classified as
having serious illness among patients admitted with a diagnosis of
falciparum malaria, and absence of the same with a diagnosis of vivax
malaria. Legend lists groups according to year of age.
Table 3
Odds of fatal outcome with serious illness with a diagnosis of fal-




Plasmodium falciparum 46 354
Plasmodium vivax 18 181
OR (95% CI) 1.3 (0.7–2.5)
*OR = odds ratio; CI = confidence interval.
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lower than those among the patients with falciparum malaria
(Figure 6), and a substantially lower risk of serious illness with
a diagnosis of vivax malaria appeared (Table 2). Likewise, risk
of serious illness showed a sharply age-dependent pattern
among patients with a diagnosis of P. falciparum but not with
P. vivax (Figure 3). Collectively, these findings suggest that
serious and fatal illness associated with P. vivax was not often
misdiagnosed P. falciparum or a mixed infection dominated by
that parasite.
Co-infection by other endemic infectious agents cannot be
ruled out among the patients at Karitas Hospital diagnosed
with malaria. The proportion of patients receiving presumptive
antibiotic therapy with a confirmed diagnosis of falciparum or
vivax malaria was just 15% and 28%, respectively, whereas
90% and 92% of patients classified as seriously ill recovered
after therapy for that diagnosis. Although spontaneous recov-
ery from less threatening infections cannot be ruled out, most
of these recoveries appear attributable to antimalarial therapy.
Figure 4. Charts illustrate the relative frequencies of syndromes among patients classified as having serious illness with a diagnosis of
falciparum or vivax malaria.
Table 4
Distribution of multiple serious and fatal malaria syndromes*
Syndromes (per patient)
Serious Fatal
PF PV Mix PF PV Mix
1 359 191 13 36 16 2
2 40 8 2 10 2 0
3 1 0 0 0 0
Total 400 199 15 46 18 2
*PF = Plasmodium falciparum; PV = Plasmodium vivax.
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That relationship would point to the plasmodia as the domi-
nant etiologic agent.
Among fatalities, however, death obviously occurred
despite such therapy and the likelihood of other endemic
infections playing a role in that outcome cannot be ruled out.
Studies elsewhere,22–24 however, evaluated fatal cases for the
most common endemic co-infections and found few other
causes of death more likely than P. vivax. Those fatalities
exhibited the same range of syndromes observed among the
seriously ill patients with a diagnosis of vivax malaria in West
Sumba. The proportion of patients classified as having seri-
ous illness and suffering a fatal outcome (11.5% with a
diagnosis of P. falciparum; 9.0% for P. vivax) accorded with
similar frequencies in other hospital-based studies (6–10%
for P. falciparum; 8–11% for P. vivax).6–10
Clinical studies support a relationship between serious ill-
ness and risk of death with vivax malaria. Rates of reported
death under vivax malaria therapy for neurosyphilis in patients
during the 1920s and 1930s show consistency with the data
from hospitals in endemic zones today. The therapeutic effi-
cacy of induced malaria for tertiary syphilis, an otherwise fatal
disease before antibiotics, was only about 35% and hinged
upon the severity and number of malaria paroxysms.25 Prac-
titioners were therefore relatively aggressive with malaria
therapy, and those patients may be considered to have expe-
rienced relatively severe disease.26 The 5–10% case fatality
rates among patients classified as seriously ill with a diagnosis
of vivax malaria among patients in endemic zones today
approximates the 5–15% rates observed among many thou-
sands of patients challenged with P. vivax for therapy of
tertiary syphilis.27–34
As with death caused by many infectious agents, such
extremes of virulence by the parasites that cause malaria may
hinge upon complex host genetic, nutritional, immunologi-
cal, and many other factors, as well as co-infections or other
underlying disease states. The study at Karitas Hospital does
not confirm P. vivax as the sole agent of serious and fatal
illness in any patient. Indeed, this may be unlikely with either
species of parasite, and the observed relative weights of asso-
ciation with serious and fatal illness may encourage and guide
more detailed prospective analyses of this question.
A diagnosis of falciparum malaria carried a higher risk
of serious illness among hospitalized patients (OR = 2.9; 95%
CI = 2.4–3.5), but vivax malaria was nonetheless associated
with 32% of that burden. Risk of death among patients with
falciparum malaria and classified as having serious illness
was indistinguishable from patients with a diagnosis of vivax
malaria (OR = 1.3; 95% CI = 0.7–2.5). These findings
accorded with a similar retrospective study from Jayapura,
Papua; OR = 2.8; 95% CI: 2.0–3.0 for severe disease with fal-
ciparum versus vivax malaria, and OR = 0.9; 95% CI: 0.4–2.1
Figure 5. Distribution of available hemoglobin measurements
among patients classified as having serious illness by any syndrome.
The hashed vertical line represents the thresholds for severe anemia
among adults and children.
Figure 6. Frequency of parasitemias exceeding ~6,000 parasites/mL
among patients with not serious, serious, and fatal infections by
Plasmodium falciparum or Plasmodium vivax.
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for risk of death with those diagnoses.6 In a 4-year prospective
hospital-based study at Timika, Papua in eastern Indonesia,7
admitted patients were slightly less likely to be classified as
having severe disease with a diagnosis of falciparum versus
vivax malaria (OR = 0.8; 95% CI: 0.8–0.9), but equally likely
to suffer death with that classification (OR = 1.3; 95% CI: 0.9–
1.8). The rates of severe and fatal falciparum malaria among
the seriously ill at Timika (20% and 11%) generally accorded
with those observed at Karitas hospital (26% and 12%), as did
those with vivax malaria; 23% and 7% at Timika, and 11%
and 9% at West Sumba. Unlike the study at Timika,7 young
children at Karitas hospital were not strikingly more suscepti-
ble to serious illness associated with vivax malaria, even
though such a pattern was clearly evident with falciparum
malaria (Figure 3). Further surveys of malaria morbidity and
mortality at other hospitals in the region are required to estab-
lish such frequencies as general trends in eastern Indonesian
endemic zones.
The spectrum of syndromes among seriously ill patients
with vivax or falciparum malaria resembled those observed
in the prospective hospital-based study from Timika, Papua
in eastern Indonesia, and in the Sepik region of Papua New
Guinea7,8; severe anemia dominated and altered mental
state syndromes figured prominently in the study. Records of
most patients at Sumba did not include thrombocyte counts,
but hemorrhage was documented in some patients with vivax
malaria. Sometimes severe thrombocytopenia is a well known
and prominent, if not dominant, feature of acute vivax malaria
in hospitalized patients.35 The relatively lower frequencies of
multiple organ involvement in this study may reflect the rela-
tive insensitivity of the classifications as a consequence of the
few laboratory assessments available at Karitas Hospital.
In summary, this retrospective study of the 24-month malaria
experience of a single hospital in eastern Indonesia suggests
P. vivax, along with myriad possible co-determinants, con-
tributes substantially to the burdens of hospitalizations, serious
illness, and death associated with the malaria endemic to this
community. Although risk of serious illness with a diagnosis of
vivax malaria was significantly less than with that of falciparum
malaria, risk of death among patients with serious disease was
approximately equal between those diagnoses. Infants, chil-
dren, and adolescents bore most of the burdens of serious and
fatal illness associated with falciparum malaria, whereas all age
groups appeared vulnerable to serious and fatal illness asso-
ciated with vivax malaria. Despite the perception of vivax
malaria as a benign infection, this parasite may be contributing
to or causing serious and fatal illness in eastern Indonesia.
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